Skip navigation

Arecor Announces the Inaugural Formation of a Global Diabetes Scientific Advisory Board

11 September 2017

Cambridge, UK, 08 September 2017: Arecor Ltd, the leading formulation technology company, focussed on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, announces the inaugural formation of a Global Diabetes Scientific Advisory Board (“SAB”) to support the scientific, pre-clinical and clinical development of its proprietary superior diabetes products to better improve the quality of life of those living with diabetes. The SAB brings together three world-renowned scientists and endocrinologists from the US and EU with extensive expertise in the field of diabetes and related conditions.


"Constituting our SAB is an important step in helping to drive forward our diabetes product development plans and we are delighted to have brought together such eminent thought leaders in the field, to form this world-class SAB.  The Advisory Board will help Arecor maximise the clinical impact of our programmes in the treatment of this debilitating disease, as well as helping us identify new opportunities for our proven formulation expertise and proprietary platform technology”, commented Dr Sarah Howell, Chief Executive Officer of Arecor.   “The SAB’s international expertise brings a deep understanding of and insight into the disease that will provide invaluable input into future patient clinical trials as we look to address significant unmet need”.

“Arecor’s work to develop formulations of commercially viable ultra-concentrated rapid acting insulins, along with its stable liquid glucagon product, represent exciting new progress in the field of diabetes that should facilitate important new treatment regimens and offer greater control of blood glucose to diabetes patients”, added Dr Thomas Pieber, Chairman of Endocrinology and Metabolism at the Medical University of Graz and member of the SAB, "I look forward to working with this outstanding group of scientists and contributing to the development and progress of Arecor’s work”.

The members of Arecor’s Scientific Advisory Board are:
Bruce Buckingham, MD, is Professor of Paediatrics (Endocrinology) at the Lucile Salter Packard Children’s Hospital, Stanford University School of Medicine.  His major interest is in type 1 diabetes mellitus, continuous glucose sensor, and the development of an artificial pancreas. Other research interests include using continuous glucose monitoring and algorithms to control blood glucose levels in intensive care units. He is currently working on the clinical trial: Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes.
 
Eda Cengiz, MD, is Associate Professor of Paediatrics (Endocrinology) at the Yale School of Medicine, Yale University.  She is a Fellow of Brown Medical School / Hasbro Children’s Hospital and is an Elected Board Member (2016) of the International Society for Paediatric and Adolescent Diabetes.  Her prospectively designed clinical study (Early Cardiovascular Disease Markers for Children with Type 1 Diabetes (Jerusalem, Israel) (2009 - 2012), investigates signs of early cardiovascular disease in children with type 1 diabetes in the US and in Israel.

Thomas R. Pieber, MD, is a clinical specialist in endocrinology and diabetes mellitus whose research is dedicated to the relationship of inflammation, energy homeostasis and human diseases. His group has developed a novel technique called open-flow microperfusion (OFM) which is used to explore energy metabolism in adipose and muscle tissue in diabetes. Recently his research also addressed the role of 15-hydroxy-vitamin D in immune tolerance and autoimmunity. In a joint research effort with leading obesity centers in Europe his group currently addresses the role of immune competent cells and novel pathways of chronic inflammation in obesity and diabetes. Dr Pieber is Chairman of the Division of Endocrinology and Metabolism at the Medical University of Graz.

The 53rd Annual Meeting of the European Association for the Study of Diabetes (“EASD”) will take place from 11 to 15 September 2017 in Lisbon, Portugal

Both Dr Sarah Howell and Dr Thomas Pieber will be attending the meeting and would welcome enquiries. They can be contacted on sarah.howell@arecor.com and thomas.pieber@medunigraz.at respectively.
EASD is the largest international scientific meeting on diabetes and its complications, bringing researchers and clinicians together of the highest calibre and presenting a programme that includes stimulating symposia, keynote lectures and debates covering both basic and clinical science.
 
EASD is committed to improving the lives of all people with diabetes, ensuring that a broad spectrum of safe and effective therapies is available to meet the needs of the diverse population affected by this disease. Please visit www.easd.org for more information.

For more information, please contact: 

Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426 060

Peckwater PR tarquin.edwards@peckwaterpr.co.uk
Tarquin Edwards Tel: +44 (0) 7879 458 364

About Arecor
Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.  Arecor's product portfolio also includes:

Stable aqueous glucagon for emergency and artificial pancreas use, 

Novel insulin formulations to deliver ultra-rapid acting insulin analogs and; 

Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.